References
- Wise R, Ballard RC. Review of the in vitro evaluation of FCE 22101. J Antimicrob Chemother 1989; 23, Supplement C: 7–13.
- Franceschi G, Perrone E, Alpegiani M, Bedischi A, Battistini C, Zarini F, Della Bruna C. Synthesis and antimicrobial spectrum of FCE 22101 and its orally available ester FCE 22101. J Antimicrob Chemother 1989; 23, Supplement C: 1–6.
- Philippon A, Ben Redjeb S, Fournir G, Ben Hassen A. Epidemiology of extended spectrum β-lactamases. Infection 1989; 17: 347–354.
- Payne DJ, Amyes SGB. Transferable resistance to extended spectrum β-lactams: a major threat or a minor inconvenience? J Antimicrob Chemother 1991; 27: 255–261.
- Vatopuolos AC, Philippon A, Tzouvelekis LS, Komninou A, Legakis NJ. Prevalence of transferable SHV-5 type β-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece. J Antimicrob Chemother 1990; 26: 635–648.
- Young Y, Livermore DM. Interactions of FCE 22101 with class I B-lactamases. J Antimicrob Chemother 1989; 23, Supplement C: 85–94.
- Jarliér V, Nicholas NV, Philippon A, Girsoir AM, Grosset J. In vitro activity of FCE 22101 and other β-lactam antibiotics against enterobacteriaceae resistant to third generation cephalosporins. J Antimicrob Chemother 1989; 24: 165–172.